A new meta-analysis of more than 6000 studies shows that oral contraceptives significantly reduce the risk of ovarian cancer. The risk reduction increases proportionally with duration of use.
See the abstract here
Related Topics
Action Alert: Urge Congress to Support the Ovarian Cancer IMPACT Act
After months of dedicated advocacy alongside survivors, families, and clinicians, the bipartisan Ovarian Cancer Improving and Modernizing Prevention, Access, Care, and Testing (IMPACT) Act has officially been introduced in Congress. Championed by Senators Elissa Slotkin (D-MI) and Katie Britt (R-AL) in the Senate, and Representatives Rosa DeLauro (D-CT-03) and Don Bacon (R-NE-01) in the House, this bill … Continued
Bipartisan Legislation Introduced to Improve Prevention, Testing and Care for Gynecologic Cancers
Ovarian Cancer IMPACT Act would expand access to genetic testing and counseling, risk-reducing care, education and specialized care for patients and families WASHINGTON, D.C. — September 29, 2026 — Ovarian Cancer Research Alliance (OCRA) today joined patients, survivors, and advocates in celebrating the introduction of the Ovarian Cancer Improving and Modernizing Prevention, Access, Care, and Testing … Continued
OCRA’s Advocate’s Corner: September 2026
Written by Julia Thayer, OCRA’s Associate Director, Advocacy September is Ovarian Cancer Awareness Month and Gynecologic Cancer Awareness Month. It is a time to not only honor everyone impacted by these diseases, but also remember those we have lost and recommit ourselves to creating meaningful change. Bipartisan Ovarian Cancer IMPACT Act Introduced in Congress This month, … Continued